腹腔热灌注联合静脉化疗治疗晚期卵巢癌的临床效果观察

目的 探究腹腔热灌注联合静脉化疗治疗晚期卵巢癌的临床效果.方法 选择2015年2月至2016年2月我院收治的52例晚期卵巢癌患者为研究对象,将其分成两组,对照组使用TP法实施静脉化疗,观察组使用腹腔热灌注联合静脉化疗法进行治疗,对比两组患者的肿瘤控制、腹水控制以及不良反应发生情况.结果 观察组患者的肿瘤控制率为80.77％,对照组为50.00％,组间数据存在统计学差异(P＜0.05).观察组患者腹水控制率为73.08％,对照组为46.15％,组间数据存在统计学差异(P＜0.05).两组患者不良反应发生率不存在统计学差异(P＞0.05).结论 对于晚期卵巢癌患者,使用腹腔热灌注联合静脉化疗法进行治疗,可以取得较为满意的临床效果,安全性强,操作简单,对于提升患者生存质量来讲,有着非常重要的现实意义存在,值得进一步推广使用.

Effect observation of hyperthermic peritoneal perfusion combined with intravenous chemotherapy in the treatment of advanced ovarian cancer

Objective To probe into clinical efficacy of hyperthermic peritoneal perfusion combined with intravenous chemotherapy in the treatment of advanced ovarian cancer.Methods 52 patients with advanced ovarian cancer in our hospital from February 2015 to February 2016 were selected as the research object,and divided into two groups.Control group was treated with intravenous chemotherapy (TP method),observation group was treated with hyperthermic peritoneal perfusion combined with intravenous chemotherapy.Compared tumor control,ascites control,and adverse reactions of two groups.Results The tumor control rate of observation group was 80.77％,that of control group was 50.00％,with statistically significant difference between two groups (P＜0.05).The ascites control rate of observation group was 73.08％,that of control group was 46.15％,with statistically significant difference between two groups (P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between two groups (P＞0.05).Conclusion For patients with advanced ovarian cancer,hyperthermic peritoneal perfusion combined with intravenous chemotherapy,can obtain more satisfactory clinical effect,with high safety and simple operation,has very important practical significance for improving the life quality,worthy of further promotion.